Overview

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ADCT-901 in Participants With Selected Advanced Solid Tumors

Status:
Recruiting
Trial end date:
2025-04-05
Target enrollment:
Participant gender:
Summary
The primary objectives of this study are to identify the recommended dose for expansion (RDE) (and recommended schedule) and/or maximum tolerated dose (MTD), and to characterize the safety and tolerability of ADCT-901.
Phase:
Phase 1
Details
Lead Sponsor:
ADC Therapeutics S.A.